Receptos Gains 2%, CEO Touts Phase II Trials
February 27, 2015 at 11:58 AM EST
Receptos Inc (NASDAQ: RCPT) gained more than 2 percent after its chief executive said recent data on a promising colitis drug ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.